Regorafenib治疗肝癌的临床研究进展

祁兴顺; 贾佳; 刘雷; 陈辉; 柏明; 樊代明; 韩国宏

doi:10.3969/j.issn.1001-5256.2014.03.007

Regorafenib治疗肝癌的临床研究进展

DOI: 10.3969/j.issn.1001-5256.2014.03.007

第四军医大学西京消化病医院

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3379
- HTML全文浏览量: 13
- PDF下载量: 663
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Regorafenib for treatment of hepatocellular carcinoma: an overview of clinical trials

摘要

摘要:
Regorafenib是1种新型的多激酶抑制剂,已被批准用于转移性结肠癌和胃肠道间质瘤的治疗。旨在总结Regorafenib治疗肝癌的临床研究进展。Ⅰ期和Ⅱ期临床试验已证实Regorafenib在肝癌患者中的安全性。Ⅱ期临床试验也显示Regorafenib作为肝癌患者的二线治疗手段可以较好地控制肿瘤的进展。1项正在进行的Ⅲ期随机对照试验将比较Regorafenib与安慰剂之间作为晚期肝癌的二线治疗手段的安全性和有效性。研究分析表明Regorafenib可以有效地控制肝癌进展,有望成为晚期肝癌的二线治疗手段。
- 肝肿瘤 /
- 蛋白激酶抑制剂 /
- 临床试验 /
- 综述
Abstract:
Regorafenib, a novel multi- kinase inhibitor, has been approved for the treatment of metastatic colorectal cancer and gastrointestinal stromal tumors. The clinical trials of Regorafenib for the treatment of hepatocellular carcinoma ( HCC) are summarized. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety of Regorafenib in patients with HCC. A phase Ⅱ clinical trial has shown that as a second-line therapy for HCC, Regorafenib can achieve a relatively high disease control rate. In addition, an ongoing phase Ⅲ randomized, controlled trial will compare the safety and efficacy between Regorafenib and placebo as second- line therapies for advanced HCC. These results indicate that Regorafenib can effectively control the progression of HCC and may be used as a second- line therapy for advanced HCC.
- liver neoplasms /
- protein kinase inhibitors /
- clinical trial /
- review

HTML全文

参考文献(15)

[1]SIROHI B, PHILIP DS, SHRIKHANDE SV.Regorafenib:carving a niche in the crowded therapeutic landscape[J].Expert Rev Anticancer Ther, 2013, 13 (4) :385-393.

[2]WILHELM SM, DUMAS J, ADNANE L, et al.Regorafenib (BAY73-4506) :a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].Int J Cancer, 2011, 129 (1) :245-255.

[3]VILLANUEVA MT.Gastrointestinal cancer:regorafenib, the CORRECT way forward or just another GRIDlock?[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (1) :1.

[4]GROTHEY A, van CUTSEM E, SOBRERO A, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :303-312.

[5]ZAKI K, ASLAM S, EISEN T.Regorafenib (BAY 73-4506) :stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma[J].Curr Oncol Rep, 2013, 15 (2) :91-97.

[6]DAVIS SL, ECKHARDT SG, MESSERSMITH WA, et al.The development of regorafenib and its current and potential future role in cancer therapy[J].Drugs Today (Barc) , 2013, 49 (2) :105-115.

[7]DEMETRI GD, REICHARDT P, KANG YK, et al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) :an international, multicentre, randomised, placebo-controlled, phase 3 trial[J].Lancet, 2013, 381 (9863) :295-302.

[8]MROSS K, FROST A, STEINBILD S, et al.A phase I dose-escalation study of regorafenib (BAY 73-4506) , an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors[J].Clin Cancer Res, 2012, 18 (9) :2658-2667.

[9]SUNAKAWA Y, FURUSE J, OKUSAKA T, et al.Regorafenib in Japanese patients with solid tumors:phase I study of safety, efficacy, and pharmacokinetics[J].Invest New Drugs, 2013, 32 (1) :104-112.

[10]SHIMIZU T, TOLCHER AW, PATNAIK A, et al.Phase I doseescalation study of continuously administered regorafenib (BAY 73-4506) , an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors[J].J Clin Oncol, 2010, 28 (Suppl 15) :3035-2025.

[11]FINN RS, BLUMENSCHEIN GR, TOLCHER AW, et al.Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC) :Phase I safety and pharmacokinetic (PK) study[J].J Clin Oncol, 2013, 31 (Suppl 4) :300.

[12]GEORGE S, WANG Q, HEINRICH MC, et al.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib:a multicenter phase II trial[J].J Clin Oncol, 2012, 30 (19) :2401-2407.

[13]EISEN T, JOENSUU H, NATHAN PD, et al.Regorafenib for patients with previously untreated metastatic or unresectable renalcell carcinoma:a single-group phase 2 trial[J].Lancet Oncol, 2012, 13 (10) :1055-1062.

[14]BRUIX J, TAK WY, GASBARRINI A, et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:Multicentre, open-label, phase II safety study[J].Eur J Cancer, 2013, 49 (16) :3412-3419.

[15]CHENG AL, FINN RS, KUDO M, et al.Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib:An ongoing randomized, double-blind, phase III trial[J].J Clin Oncol, 2013, 31 (Suppl 15) :4163.

施引文献

资源附件(0)

访问统计